The Technical Analyst
Forma Therapeutics [FMTX]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Forma Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $20.01
/ 13 okt 2022 @ 16:00
| RATING 2022-10-21 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.24 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -5.24 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 19.57 - 20.45 ( +/- 2.21%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-10-14 | Lesser Brian Andrew | Sell | 42 593 | Common Stock |
| 2022-10-14 | Lesser Brian Andrew | Sell | 37 500 | Stock Option (Right to Buy) |
| 2022-10-14 | Potts Jeannette | Sell | 37 500 | Stock Option (Right to Buy) |
| 2022-10-14 | Potts Jeannette | Sell | 43 958 | Common Stock |
| 2022-10-14 | Fanucci Marsha | Sell | 7 250 | Common Stock |
| INSIDER POWER |
|---|
| -93.80 |
| Last 97 transactions |
| Buy: 1 770 820 | Sell: 4 300 300 |
Forecast:
01:40 - $21.00
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $20.01 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 1.553 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FMTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FMTX
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
Latest Press Releases
2022-10-14 08:35:00 - Press Release
Novo Nordisk Announces The Completion Of The Forma Therapeutics Acquisition
BagsvÆrd, denmark, 14 october 2022 – novo nordisk today announced that the acquisition of forma therapeutics holdings, inc. (forma), announced on 1 september 2022, has been completed.
2022-09-27 11:42:00 - Press Release
Forma Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Forma Therapeutics, Holdings Inc. - Fmtx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of forma therapeutics, holdings inc. (nasdaqgm: fmtx) to novo nordisk a/s (nyse: nvo). under the terms of the proposed transaction, shareholders of forma will receive $20 in cash for each share of forma that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequa
2022-09-26 00:00:00 - Press Release
Shareholder Investigation: Halper Sadeh Llc Investigates Gmtx, Fmtx, Trq, Sgfy
New york , sept. 26, 2022 /prnewswire/ -- halper sadeh llc, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: gemini therapeutics, inc. (nasdaq: gmtx) 's merger with disc medicine, inc. pre-merger gemini shareholders are expected to own approximately 28% of the combined company.
2022-09-19 01:43:00 - Press Release
Shareholder Investigation: Halper Sadeh Llc Investigates Iea, Cybe, Fmtx, Trq
New york , sept. 19, 2022 /prnewswire/ -- halper sadeh llc, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: infrastructure & energy alternatives, inc. (nasdaq: iea) 's sale to mastec for $10.50 per share in cash and 0.0483 of a mastec share for each iea share.
2022-09-02 15:46:00 - Press Release
Forma Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Forma Therapeutics, Holdings Inc. - Fmtx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of forma therapeutics, holdings inc. (nasdaqgm: fmtx) to novo nordisk a/s (nyse: nvo). under the terms of the proposed transaction, shareholders of forma will receive $20 in cash for each share of forma that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequa
Latest News
2022-09-02 22:38:36 - Invezz
Forma Therapeutics shares jump 50%; here is why
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) shares are up 50% after announcing a definitive agreement with Novo Nordisk.
2022-09-01 14:36:07 - The Motley Fool
Why Forma Therapeutics Holdings Stock Is On Fire Today
2022-09-01 12:14:05 - Investors Business Daily
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. The post Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout appeared first on Investor's Business Daily.
2022-09-01 09:20:18 - Pulse2
Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion
Novo Nordisk (NYSE: NVO) is buying Forma Therapeutics, Holdings Inc (Nasdaq: FMTX) for $1.1 billion. This is why.
2022-09-01 08:19:00 - Reuters
Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal
Danish drugmaker Novo Nordisk will acquire Forma Therapeutics in a deal valued at $1.1 billion to expand its rare blood disorders portfolio, the companies said on Thursday.
2022-09-01 08:18:27 - Market Watch
Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion
Forma Therapeutics Holdings Inc. FMTX, +1.67% announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk NVO, +0.06% NOVO.B, -0.59% in a deal with an equity value of $1.1 billion. Forma shares are halted for news until 8:30 a.m.
2022-08-31 10:32:49 - Seeking Alpha
Forma Therapeutics: Rare Disease Play
2022-08-05 10:21:10 - Seeking Alpha
Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q2 2022 Results - Earnings Call Transcript
Forma Therapeutics Holdings Inc. (NASDAQ:FMTX ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Adam Bero - Investor Relations Frank Lee - President and Chief Executive Officer Agustin Melian - Executive Vice President, Research and Development Cameron Trenor - Executive Director, Clinical Development Dave Cook - Chief Scientific Officer Todd Shegog - Chief Financial Officer Conference Call Participants Mark Breidenbach - Oppenheimer Maury Raycroft - Jefferies Andrew Berens - SVB Prakhar Agrawal - Cantor Operator Good morning, my name is Josh and I will be your conference operator today. At this time, I would like to welcome everyone to the Forma Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call.
2022-07-29 07:05:00 - Business Wire
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
2022-06-22 11:35:20 - Zacks Investment Research
Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 536% in Forma Therapeutics Holdings, Inc. (FMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.